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Abstract
Background: p63, a member of the p53 protein family, plays key roles in epithelial development and
carcinogenesis. In breast cancer, p63 expression has been found predominantly in basal-A (epithelial-type) triple-
negative breast carcinomas (TNBC). To investigate the functional role of p63 in basal-A TNBC, we created MDA-MB-
468 cell lines with inducible expression of the two major N-terminal p63 isoforms, TAp63α and ΔNp63α.
Results: TAp63α did not have significant effect on gene expression profile and cell phenotype, whilst the main
effect of ΔNp63α was reduction of cell adhesion. Gene expression profiling revealed genes involved in cell
adhesion and migration whose expression relies on overexpression of ΔNp63α. Reduced cell adhesion also led to
decreased cell proliferation in vitro and in vivo. Similar data were obtained in another basal-A cell line, BT-20, but
not in BT-549 basal-B (mesenchymal-like) TNBC cells.
Conclusions: In basal-A TNBC cells, ΔNp63α has much stronger effects on gene expression than TAp63α. Although
p63 is mentioned mostly in connection with breast cell differentiation and stem cell regulation, we showed that a
major effect of p63 is regulation of cell adhesion, a process important in metastasis and invasion of tumour cells.
That this effect is not seen in mesenchymal-type TNBC cells suggests lineage-dependent functions, mirroring the
expression of ΔNp63α in primary human breast cancers.
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Background
p63 is a member of the p53 family of transcription factors
and is known to be involved in the regulation of epithelial
development and carcinogenesis. The TP63 gene is
expressed as a spectrum of protein isoforms due to alter-
native promoter usage and alternative splicing at the 3´
end of the transcript [1]. There are two N-terminal pro-
tein isoforms: TAp63, containing a p53-like N-terminal
transactivation domain, and ΔNp63, the N-terminally
truncated isoform that lacks this transactivation domain.
ΔNp63 was originally thought to be only a dominant
negative inhibitor that blocks the function of full-length
p53/p63/p73 proteins. Later it was found that ΔNp63 also
transactivates target genes due to the presence of alterna-
tive transactivation domains [2, 3] and that it is the pre-
dominant isoform in most normal adult tissues according
to immunohistochemical studies [4, 5]. Compared to
ΔNp63, TAp63 is expressed as the main isoform only in
specific cell types such as germ cells and B-lymphocytes
[4, 6, 7]. Similarly, ΔNp63 is overexpressed in many
cancers, especially squamous carcinomas [5, 8] in contrast
to TAp63 which is usually detected in tumour tissue at
low level excepting B-cell lymphomas [5, 9].
In normal breast tissue, ΔNp63 expression is restricted
to basal/myoepithelial cells [5, 10, 11] and p63 is essential
for mammary gland morphogenesis during embryonic
development [12]. In adulthood, ΔNp63 is important for
maintenance of basal cell characteristics of breast epithe-
lial cells [13], for correct luminal cell proliferation and
differentiation during lactation when it regulates paracrine
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basal-to-luminal cell signalling [14], and as a pro-survival
factor of multipotent progenitor cells during post-
lactational involution [15]. ΔNp63 expression is also
linked with mammary stem cells – in mammary tissue
ΔNp63 is expressed in the basal cell layer which is thought
to contain stem cells [16], its expression was detected in
activated stem cells isolated from developing mouse mam-
mary tissue [17] and in stem cells isolated from mouse
mammary epithelial cell line [18]. Moreover, Thomas et al.
have isolated p63-positive stem cell-like multi-potent cells
from breast milk [19] and Li et al. identified reciprocal
interactions between p63 isoforms and hedgehog signal-
ling in mammary stem and progenitor cells that regulate
initiation and progression of the mammary regenerative
cycle. In this situation, ΔNp63 blocks and TAp63 pro-
motes differentiation along the luminal lineage [20].
In breast cancer, ΔNp63 is highly expressed in a subset
of tumours with metaplastic and basal-like features that
are frequently triple-negative [21–24]. Triple-negative
breast cancers (TNBC) are defined by lack of estrogen
receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2). TNBC are
highly proliferative, biologically more aggressive and
exhibit poor prognosis compared to other types of breast
cancer [25, 26]. With no targeted treatments currently
available, patients with TNBC have a high risk of relapse
and shorter overall survival compared to other breast
cancer subtypes [27].
Concerning the role of p63 in breast cancer cells,
ΔNp63 has been proposed as a pro-tumourigenic tran-
scription factor that promotes cancer stem cell (CSC)
features [21]. Consistent with this notion, ΔNp63 pro-
motes normal mammary stem cell activity by enhance-
ment of Wnt signalling and through this mechanism
governs tumour-initiating activity of basal-like breast
cancer [28]. In general agreement with these findings,
abrogation of endogenous ΔNp63 causes a switch
towards luminal phenotype and away from the basal
phenotype in basal breast cancer cells, indicating a role
in lineage regulation, although p63 silencing was insuf-
ficient to cause full luminal-type differentiation [29].
Further, ΔNp63 acts as a survival factor in a subset of
breast cancers by antagonizing p73-mediated apoptosis
[23]. In contrast, Buckley et al. have shown that ΔNp63
cooperates with BRCA1 to regulate growth control and
maintain genomic stability in normal breast cells [30].
They also suggested that defects in BRCA1-ΔNp63
signalling are key events in the pathogenesis of basal-like
breast cancer. In agreement with this idea, ΔNp63 and
ΔNp73 up-regulate key DNA damage repair proteins
(BRCA2, RAD50, RAD51, mre11, ATM) [31, 32] and loss
of p63/p73 promotes mammary tumour formation in
mice [33]. p63 has also been shown to play a tumour
suppressor role in breast cancers because abrogation of its
function through interaction with mutant p53-SMAD
complex led to enhanced metastasis [34].
In view of the wide-ranging roles and effects of p63 that
have been proposed in normal breast and TNBC, defini-
tive roles for ΔNp63 and TAp63 in basal-type breast
cancer need to be clarified. In our work we further eluci-
dated the role of these two p63 isoforms in TNBC cells.
Methods
Cell culture conditions, vectors and transfections, beta-
galactosidase assay
MDA-MB-468, BT-20 and BT-549 breast carcinoma cells
were obtained from ATCC and maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % fetal bovine serum (HyClone, Thermo Scientific,
USA), 1 mM sodium pyruvate (Sigma Aldrich, USA) and
penicillin/streptomycin (HyClone, Thermo Scientific, USA)
at 37 °C in CO2 incubator in humidified atmosphere.
To generate clones with inducible expression of ΔNp63α
and TAp63α, MDA-MB-468 cells were transfected with
pcDNA6/TR (Life Technologies, USA) vector and selected
with blasticidin (5 μg/ml) for three weeks. Resistant col-
onies were picked and expanded for further analysis under
selective conditions. Beta-galactosidase assay was used to
test the inducibility of stable transfectants. MDA-MB-468-
pcDNA6/TR cells were transiently transfected with pT-
REx/GW-30/lacZ vector (Life Technologies, USA), lacZ
expression was induced by incubation in DMEM with
1 μg/ml tetracycline for 24 h. Cells were fixed in PBS
supplemented with 5 mM EDTA, 20 mM MgCl2 and
0,2 % glutaraldehyde for 10 min, washed in PBS and incu-
bated in staining buffer (0,1 M phosphate buffer supple-
mented with 2 mM MgCl2, 5 mM potassium ferrocyanide,
5 mM potassium ferricyanide and 1 mg/ml X-gal sub-
strate) for 30 min at room temperature. Development of
blue colour was checked under light microscope. MDA-
MB-468-pcDNA6/TR cells were then transfected with pT-
REx-DEST30-ΔNp63α and pT-REx-DEST30-TAp63α
vectors (containing full length cDNAs coding for human
TAp63α and ΔNp63α; prepared from pT-REx-DEST30
using Gateway cloning technology, both from Life
Technologies, USA) and transfected cultures were selected
with G418 (500 μg/ml) for three weeks. Resistant colonies
were picked, expanded under selective conditions and
tested for inducibility of p63 expression by Western blot.
pcDNA3-ΔNp63α and pcDNA3-GFP vectors were used
for transient transfections of BT-20 and BT-549, cells were
analysed 24 h after transfection. All transfections were
performed using Amaxa Nucleofector Technology (Lonza,
Switzerland) according to the manufacturer’s instructions.
SDS-PAGE and Western blotting
Cells were harvested directly into lysis buffer (150 mM
NaCl, 1 % Nonidet P-40, 50 mM Tris-HCl pH 8.0, 5 mM
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EDTA pH 8.0, protease inhibitor cocktail) and 20 μg of
total protein in NuPAGE LDS Sample Buffer (Life
Technologies, USA) loaded on 10 % polyacrylamide gels,
separated and transferred onto nitrocellulose membranes
in Mini-PROTEAN Electrophoresis System (Bio-Rad,
USA) for 90 min applying 100 V in transfer buffer
(240 mM Tris, 190 mM glycine, 20 % methanol). Mem-
branes were blocked in 5 % non-fat milk in PBS with
0.1 % Tween and incubated overnight with primary anti-
bodies at 4 °C. Primary antibodies used: anti-p63 clone
SFI-6 (DCS Innovative Diagnostik-Systeme, Germany),
anti-TAp63 clone TAp63-4.1 and anti-ΔNp63 clone
ΔNp63-1.1 and polyclonal ΔNp63-44 [4] and anti-actin
AC40 (Sigma-Aldrich, USA). Membranes were then
incubated with appropriate HRP-conjugated secondary
antibodies (RAM-Px, SWAR-Px, Dako, Denmark) diluted
1 : 1000 for 1 h at room temperature. Signal was detected
using ECL reagent (Amersham Pharmacia Biotech, UK).
Gene expression profiling
MDA-MB-468 cells were cultured with 1 μg/ml tetracyc-
line for 24 h and harvested. Total RNA was isolated using
TRI Reagent (Sigma-Aldrich, USA) and 1-bromo-3-chloro-
propane, precipitated with ethanol and diluted in RNAse-
free water. Total RNA was labelled using TargetAmp Nano
Labeling Kit for Illumina Expression BeadChip (Illumina,
USA) and subsequently used for genome-wide expression
profiling using HumanHT-12 v4 Expression BeadChip
Kit (Illumina, USA). Results were analysed using R
(The R Project for Statistical Computing), LIMMA soft-
ware package [35], MultiExperiment Viewer [36] and
GenomeStudio (Illumina, USA). Web tools from DA-
VID Bioinformatics Resources 6.7 [37] were employed
to analyse gene ontology. The experiment was per-
formed in three biological replicates.
Quantitative RT-PCR
For analysis of individual gene expression, cells were grown
for 24 h in media with 1 μg/ml tetracycline. Total RNA
was isolated using RNeasy Mini Kit (Qiagen, Netherlands).
1 μg of total RNA was converted into cDNA using Rever-
tAid H Minus Reverse Transcriptase (Thermo Fisher
Scientific, USA). Quantitative RT-PCR was performed in
technical triplicates using ABI 7900HT Fast Real Time
PCR System (Applied Biosystems, USA) and repeated
twice. Relative quantification of gene expression was per-
formed in SDS 2.3 and RQ Manager 1.2 software (Applied
Biosystems, USA) and RealTime StatMiner (Integromics,
Spain). Primers are listed in Additional file 1.
xCELLigence assay
xCELLigence system (ACEA Biosciences, USA) was used
for real-time analysis of cell adhesion and proliferation.
Before cells were seeded, background was measured
45 min after adding 50 μl media into each well of E-
plate 16. Cells were trypsinized, resuspended in DMEM,
counted using haemocytometer and 20 000 cells in
100 μl added per well. Impedance signal, which depends
on the coverage of the electrodes with cells, was mea-
sured for 48 h in 15 min intervals. Tetracycline (1 μg/
ml) was added at the beginning of the experiment (time
0). Two independent experiments were performed, each
sample was in triplicate.
Cell detachment and wound-healing assays
For cell detachment assay, cells were grown in 96-well
plate for 24 h and then treated with 1 μg/ml tetracyc-
line to induce p63 expression for 24 or 48 h. After
washing in 0.5 % EGTA in PBS, cells were incubated in
trypsin solution (0.025 % trypsin and 0.5 % EGTA in
PBS) for the indicated periods of time. Trypsinization
was stopped by adding 100 μl DMEM with 10 % FBS.
Cells were then washed in PBS, fixed in 4 % parafor-
maldehyde for 10 min, washed again in PBS and stained
with crystal violet (5 mg/ml). After washing in tap
water, cells were dried for 30 min at RT and then 2 %
SDS was used to dissolve the colour. Absorbance was
measured at 595 nm. Three independent experiments
were performed, each sample was in hexaplicate.
For wound healing assay, cells were seeded in 6-well
plates and cultured until confluent. Scratches were made
using pipette tips and phase contrast images were taken
with Eclipse Ti-E inverted microscope system (Nikon,
Japan) for 48 h at 1 h intervals.
Cell proliferation assay, viability assay and cell cycle
analysis
To compare cell proliferation, cells were grown for 24 h in
6-well plates and then treated with 1 μg/ml tetracycline to
induce p63 expression. Both adherent and detached cells
were harvested into 2 ml of DMEM 0, 24, 48 and 72 h
after tetracycline treatment and counted in haemocytom-
eter. Three independent experiments were performed.
Propidium Iodide (PI) exclusion assay was used for
measurement of cell viability after 0, 24, 48 and 72 h
treatment with 1 μg/ml tetracycline. Medium containing
floating cells was removed and attached cells were tryp-
sinized (efficiency of trypsinization was checked under
the light microscope) and pooled with the floating cells.
After addition of PI (1 μg/ml final concentration) cells
were analysed for red fluorescence by flow cytometry
(FACSVerse, BD Biosciences, USA). The percentage of
PI positive (dead) cells was determined, after exclusion
of cell debris, using FACSuite software (BD Biosciences,
USA). Two independent biological experiments were
performed, each sample was in triplicate.
For cell cycle analysis, cells were treated with 1 μg/ml
tetracycline for 24 h, trypsinized, washed in PBS and
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fixed in 70 % ethanol for 2 h on ice. After washing in
PBS, cells were resuspended in 1 ml of PI staining solu-
tion (0.1 % Triton X-100, 10 μg/ml PI, 100 μg/ml RNase
A in PBS) and incubated at RT in the dark for 30 min.
Cell cycle analysis was performed with FACSVerse using
FACSuite software (both BD Biosciences, USA) and
ModFit LT 4.0 software (Verity Software House, USA).
Two independent experiments were performed, each
sample was in triplicate.
Tumour xenografts
106 cells were resuspended in 100 μl PBS and injected
subcutaneously into the left and right flanks of 6-week
old female SCID mice. Mice were divided in 3 groups
(MDA-MB-468 parental, MDA-MB-468-ΔNp63α un-
treated and MDA-MB-468-ΔNp63α tetracycline treated).
Tumours were allowed to grow for 3 weeks after the
injections until tumour onset in all injected sites. Then,
the group of MDA-MB-468-ΔNp63α tetracycline treated
mice were orally gavaged with 0.2 ml of tetracycline
solution 10 mg/ml to induce ΔNp63 expression, on a
daily basis for the next 8 weeks. During this period
tumour volumes were measured using callipers and
calculated using the formula ½ x height x width x length.
At the end of the observation period, mice were sacri-
ficed, tumours excised and photographed.
Results
Stably transfected cell lines with inducible expression of
p63 isoforms
To study the function of p63 in TNBC cells, we created
an in vitro model that allows tight regulation of p63
expression. Because p63 is expressed predominantly in
triple-negative and basal breast tumours with an epithe-
lial phenotype (basal-A), MDA-MB-468 cell line was
chosen as parental cell line. It has an ER-, PR-, HER-
phenotype and belongs to basal-A subtype of breast tu-
mours [38] and basal-like BL1 subgroup of TNBC [39].
MDA-MB-468 cells are reported to express negligible
levels of p63 according to gene expression profiling,
RNA sequencing, qRT-PCR and western blot [40–42],
although one study identified an undefined level of
TAp63 mRNA in these cells without identifying p63
protein [43]. Because cell lines may show different
properties in different laboratories due to differences in
culture conditions, we therefore characterized our
MDA-MB-468 cells for expression of p63 isoforms by
qRT-PCR and immunochemical approaches using anti-
bodies specific for all isoforms and mono-specific anti-
bodies for TAp63 and ΔNp63, showing a lack of all
mRNA and p63 protein isoforms (Additional file 2).
Clones stably transfected with tetracycline repressor
were selected and their inducibility was subsequently
tested by beta-galactosidase assay (Fig. 1a). Inducible
ΔNp63α and TAp63α clones were subsequently pre-
pared from this tetracycline-responsive clone by trans-
fection with either pT-REx-DEST30-ΔNp63α or pT-
REx-DEST30-TAp63α as described in the materials and
methods section. Newly selected clones were tested for
p63 isoform expression after tetracycline induction
using the pan-p63 antibody SFI-6 that distinguishes
the TA and ΔN isoforms due to their different molecu-
lar weights and the isoform specific p63 antibodies
(Fig. 1b, c), and the two clones named MDA-MB-468-
ΔNp63α and MDA-MB-468-TAp63α were used for
subsequent experiments. The parental clone expressing
only tetracycline-regulated inhibitor of transcription
was named MDA-MB-468-pcDNA6/TR and used as
negative control (Fig. 1 also shows that these cells do
not contain detectable levels of endogenous p63).
ΔNp63α regulates expression of adhesion-related genes
in MDA-MB-468 cells
To map gene expression changes after induction of
ΔNp63α and TAp63α, MDA-MB-468 cells were treated
with tetracycline for 24 h and total RNA was used for
genome-wide expression analysis. By this method we
identified 428 genes whose expression changes signifi-
cantly (adjusted p values < 0.05) after overexpression of
ΔNp63α or TAp63α (Additional file 3). In both cases,
TP63 itself was the most highly up-regulated transcript
and the identification of many previously reported p63
target genes (S100A2, FGFR3, GPX2, MIR205, KRT5
etc.) in this dataset indicate good informational value
and reliability of this analysis and also of the inducible
system. Contrary to expectations that both ΔNp63α and
TAp63α will affect gene expression, we found that only
ΔNp63α significantly changed the gene expression pro-
file, with TAp63 induction leading to up-regulation of
only two genes, of which TP63 itself is one. According
to gene ontology (GO) analysis of the ΔNp63α-regulated
genes, the most significantly enriched GO terms relating
to biological processes were “cell adhesion” and “bio-
logical adhesion” (p < 0.001) (Fig. 2a). Other enriched
adhesion-related GO terms were “cell-substrate adhe-
sion” and “cell-matrix adhesion” (p < 0.05) indicating
that cell-matrix adhesion was affected more than cell-
cell adhesion. Among GO terms describing subcellular
localization of the gene product, “plasma membrane”
was the most enriched term (p < 0.001) (Fig. 2b). This is
in agreement with the assumption that many adhesion-
related proteins are transmembrane or membrane-
associated. In accordance with this, many of the identi-
fied ΔNp63α-regulated genes have been previously
found to be involved in cell adhesion, motility, cytoskel-
eton dynamics, migration and invasion (listed in Fig. 2c).
This group included genes related to cell-extracellular
matrix (ECM) adhesion and focal adhesions such as
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ITGB4 (integrin beta 4), ITGA2 (integrin alpha 2),
FERMT1 (fermitin/kindlin), BAG3 (BCL2-associated
athanogene 3), KLK5 (kallikerin-5), CLCA2 (chloride chan-
nel accessory 2), PALLD (palladin), SVIL (supervillin),TNS4
(tensin-4), TNS3 (tensin-3), LPXN (leupaxin), TLN2 (talin-
2) and CEACAM6 (carcinoembryonic antigen-related cell
adhesion molecule 6). Genes encoding proteins regulating
cell-cell adhesion include FAT2 (FAT tumour suppressor
homolog 2), DSC3 (desmocollin-3), CLDN1 (claudin-1),
CLDN8 (claudin-8), CLDN10 (claudin-10) and CGN (cingu-
lin). Selected genes from this group were confirmed as
ΔNp63α-regulated by qRT-PCR analysis (Fig. 2d). Interest-
ingly, we observed an opposite regulation of tensins TNS3
and TNS4, which are important for connection be-
tween cytoskeleton and integrins. It has been previ-
ously shown that inhibition of TNS4 expression
decreases cell migration, while inhibition of TNS3
increases cell migration [44]. Moreover,TNS4 expression
correlated with metastasis in invasive breast carcinomas.
According to our results, ΔNp63α increases TNS4 and de-
creases TNS3 expression. Among identified ΔNp63α-regu-
lated genes there was also one gene encoding miRNA,
miR-205, which is a known target of p63 in bladder [45]
and prostate carcinomas [46] and which was shown to be
down-regulated in TNBC [47] and suggested to play a
tumour suppressor role in TNBC cells [48].
ΔNp63α induces loss of adhesion and detachment of
MDA-MB-468 cells
Since ΔNp63α changed expression of adhesion-related
genes, we analysed adhesion of MDA-MB-468-ΔNp63α,
MDA-MB-468-TAp63α and MDA-MB-468-pcDNA6/TR
cells with and without tetracycline treatment. xCELLi-
gence real-time cell analysis showed that cell-index
values, which reflect the coverage of electrodes by cells,
were significantly decreased after tetracycline treatment
of MDA-MB-468-ΔNp63α and MDA-MB-468-TAp63α
cells (Fig. 3a). Cell-index started to decrease approxi-
mately 9 h after addition of tetracycline and the impact of
ΔNp63α was much higher compared to TAp63α. Tetra-
cycline itself did not influence the cell-index (Fig. 3a).
This result was confirmed by detachment assay which
measures cell adhesion based on cell sensitivity to trypsin
[49] (Fig. 3b). Absorbance measured was dependent on the
number of cells that remained adherent after trypsinization
and thus correlated with cell adhesion. We observed strong
decrease of absorbance after induction of ΔNp63α and a
smaller decrease after TAp63α induction (Fig. 3b).
To confirm these data, we also used transient expression
in another basal-A cell line, BT-20 and in a basal-B (mesen-
chymal) TNBC cell line, BT-549. Similar effects of ΔNp63α
on cell adhesion/proliferation were observed when BT-20
cells were transiently transfected with ΔNp63α and cell
index was measured by xCELLigence (Fig. 4). On the
contrary, transient transfection of BT-549 did not signifi-
cantly influence cell behaviour. These results suggest that
ΔNp63α effect is not restricted to one cell line but depends
on different molecular backgrounds.
ΔNp63α-mediated loss of cell adhesion is accompanied
by cell cycle arrest and reduced proliferation rate in vitro
and in vivo
To investigate the effect of p63 isoforms on proliferation
and viability of MDA-MB-468-ΔNp63α and MDA-MB-
468-TAp63α cells, we detected their proliferation rate,
propidium iodide (PI) exclusion and cell cycle regulation
after tetracycline treatment. Adhesion and proliferation of
MDA-MB-468-ΔNp63α were significantly decreased 48
Fig. 1 MDA-MB-468 cells with inducible expression of p63 isoforms. a MDA-MB-468-pcDNA6/TR clone with stable expression of tetracycline
repressor transiently transfected with vector encoding beta-galactosidase under control of tetracycline-inducible promoter; staining of
beta-galactosidase activity 24 h after tetracycline (TET) treatment; b, c Western blots of TAp63α and ΔNp63α in MDA-MB-468-ΔNp63α and
MDA-MB-468-TAp63α cells 24 h after tetracycline treatment; MDA-MB-468-pcDNA6/TR parental clone was used as a negative control
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and 72 h after tetracycline treatment compared to control
cells, the effect of TAp63α was only weak (Fig. 5a, b).
According to PI exclusion assay, cell viability of MDA-
MB-468-ΔNp63α cells was not affected 24 and 48 h after
tetracycline treatment, but the cells started to die 72 h
after tetracycline treatment (Fig. 5c, increased number of
PI positive cells, p < 0.05, t-test). Decreased proliferation
of MDA-MB-468-ΔNp63α cells was accompanied by cell
cycle arrest (Fig. 5d). To see whether these anti-
proliferative effects of ΔNp63α expression are detectable
also in vivo in more natural tumour environment, MDA-
MB-468-ΔNp63α cells were subcutaneously injected into
SCID mice. MDA-MB-468-ΔNp63α injected mice showed
a significant decrease in tumour size after tetracycline
treatment (p < 0.001, t-test) compared to the correspond-
ing controls (Fig. 6a, b). Induction of ΔNp63α expression
in MDA-MB-468 xenografts was confirmed by SDS-
PAGE and western blot (Fig. 6c). Moreover, GADD45A
and CDKN1A growth arrest-related genes were upregu-
lated after ΔNp63α induction (Additional file 3). Because
MDA-MB-468 cells are non-metastatic in xenografts [50],
we cannot comment on whether p63 influenced this
Fig. 2 Selected results of gene expression profiling of MDA-MB-468-ΔNp63α cells 24 h after tetracycline (TET) treatment. a Analysis of gene
ontology – most highly enriched biological processes. b Analysis of gene ontology – most highly enriched subcellular localizations of gene
products. c Genes which were previously found to be involved in regulation of cell adhesion and migration and whose expression was
significantly changed in MDA-MB-468-ΔNp63α cells. Expression of genes marked in bold was evaluated by qRT-PCR. d qRT-PCR analysis of
selected p63-regulated genes in MDA-MB-468-ΔNp63α 24 h after tetracycline treatment
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Fig. 3 Analysis of MDA-MB-468-ΔNp63α, MDA-MB-468-TAp63α and MDA-MB-468-pcDNA6/TR cell adhesion with xCELLigence system and detachment
assay. a xCELLigence real-time cell analysis; tetracycline was added at the beginning of the experiment (time 0), decrease in cell index correlated with
cell detachment; b detachment assay; decrease in absorbance correlated with cell sensitivity to trypsin and reduced cell adhesion
Fig. 4 Different effects of ΔNp63α on cell adhesion/proliferation in BT-20 and BT-549 cells. BT-20 and BT-549 cells were transiently transfected with
pcDNA3-ΔNp63α and pcDNA3-GFP plasmids and analyzed by xCELLigence 24 h after transfection. Cell index was significantly decreased in BT-20 cells
expressing ΔNp63α (p < 0.01, t-test) and MDA-MB-468-ΔNp63α cells treated with tetracycline (p < 0.01, t-test) but not in BT-549 cells expressing
ΔNp63α (p = 0.15, t-test) after 48 h. Expression of ΔNp63α 24 h after transfection / tetracycline treatment was confirmed by western blot
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process, although there was no evidence of local invasion
or overt distant metastasis in any group of mice.
Transwell migration assay with xCELLigence CIM
plates and wound-healing assay were employed to study
the effect of ΔNp63α on cell migration and invasion.
MDA-MB-468 cells have very low migratory and invasive
activity in vitro [38, 51] and transwell migration of these
cells was not measurable. Wound-healing assay did not
show any changes in cell migration after 20 h and evalu-
ation of results after longer time was not possible due to
changes in proliferation and cell detachment (Fig. 6d).
To compare resistance of MDA-MB-468 cells to
anoikis, cells were grown in suspension on bacterial
plates that did not allow them to adhere. Their viability
was measured using PI exclusion assay after 24, 48 and
72 h. We did not found any apparent correlation
between ΔNp63α expression and resistance to anoikis
(Additional file 4).
Discussion
TNBC is an aggressive form of breast cancer with
shorter median time to relapse and death compared to
other breast cancer subtypes, so there is an urgent need
to expand our knowledge of TNBC biology and molecu-
lar mechanisms involved in tumour progression and
metastasis [52]. p63 expression was previously detected
in a group of breast tumours with triple-negative pheno-
type and basal-like epithelial features and the ΔNp63/
TAp73 ratio shown to correlate with sensitivity to
cisplatin treatment in vitro [23] as well as in TNBC
patients [53]. To gain a deeper insight into the function
of p63 in TNBC cells, we have created stably transfected
Fig. 5 The effect of TAp63α and ΔNp63α expression on MDA-MB-468 cell growth, viability and cell cycle regulation. a Morphology of
MDA-MB-468-ΔNp63α, MDA-MB-468-TAp63α and MDA-MB-468-pcDNA6/TR cells after tetracycline treatment; magnification 100×; b Cell
proliferation of MDA-MB-468-ΔNp63α, MDA-MB-468-TAp63α and MDA-MB-468-pcDNA6/TR cells after tetracycline treatment (time 0); cells were
counted in suspension by haemocytometer; c Flow cytometry-based cell viability assay using propidium iodide (PI), increased ratio of PI-positive
cells correlates with decreased cell viability; d flow cytometry-based cell cycle analysis 24 h after tetracycline treatment
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MDA-MB-468 cell lines with inducible expression of
ΔNp63α and TAp63α. MDA-MB-468 cells have a triple-
negative phenotype and belong to the basal-A group of
TNBC [39]. They show also several typical features of
TNBC including mutated TP53, mutated PTEN and
EGFR overexpression [54].
Although we could see similar levels of ΔNp63α and
TAp63α induction at both the mRNA and protein levels,
genome-wide expression profiling showed that only
ΔNp63α has a significant impact on changes in gene
expression. This is contrary to the initial assumptions
that TAp63 is more active in transactivation of target
genes compared to ΔN isoforms [1] and acts to induce
apoptosis, growth arrest, and luminal differentiation in
mammary epithelium [20, 55]. However, we and others
have shown that ΔNp63 is the predominant isoform in
adult epithelial tissues, including basal breast cells and
basal-type breast cancers [4, 5, 28]. This latter paper also
showed a negligible effect of TAp63 expression in breast
epithelial cells, compared to a pro-tumorigenic role
forΔNp63. The list of genes whose expression changed
after ΔNp63α induction included many known target
genes of p63 (see Results and Additional file 3), thus
confirming the validity of our results [56–59].
Gene ontology analysis showed that ΔNp63α controls
genes involved in regulating cell adhesion. Until recently,
p63 was usually mentioned in connection with mainten-
ance of basal and progenitor/stem cell phenotype in breast
cancer cells or with cell survival and DNA damage
responses [13, 20, 21, 28]. However, it has been previously
demonstrated that p63 isoforms can regulate cell adhesion
and related processes such as cell migration and invasion
in different cancer types. p63 was shown to regulate adhe-
sion and migration-related genes in head and neck squa-
mous cell carcinoma cells and also in other squamous cell
and urothelial carcinomas [60–62]. Moreover, knock-
down of p63 caused down-regulation of cell adhesion-
associated genes, cell detachment and anoikis in non-
transformed mammary epithelial cells and keratinocytes
[63]. CD44, a cell surface glycoprotein that regulates cell
adhesion and migration and is connected to stem cell
phenotype in different tumour types including breast can-
cer, was shown to be a direct ΔNp63 transcriptional target
[64]. Most importantly, Cheung et al. have shown that
invasion of breast tumours is led by a subpopulation of
cells that are defined by their expression of basal epithelial
genes including cytokeratin 14 (K14) and p63 [65]. Inter-
estingly, although usually only a minority of cells within
breast tumours expressed basal epithelial genes, knock-
down of either K14 or p63 was sufficient to block collect-
ive invasion in primary tumour organoids. Although p63 is
a transcriptional activator of K14, the authors suggested
that p63 has K14-independent function in collective inva-
sion. As changes in cell adhesion are an important event
in the process of invasion and metastasis, we hypothesise
that changes in expression of genes involved in regulation
of cell adhesion that we have shown here could be a mech-
anism by which p63 influences cell invasion.
Fig. 6 Induction of ΔNp63α in MDA-MB-468 cells reduces tumour size in vivo and does not change cell migration. a Growth rates of MDA-MB-
468-ΔNp63α tumour xenografts in SCID mice (bars indicate standard deviation of tumour volumes, n = 6 sites injected); b representative images
of tumours excised on tumour onset and after 8 weeks of ΔNp63α induction (experimental endpoint); c detection of p63 protein level in tumour
lysates, protein extracts from corresponding cell cultures were used as controls; d representative images of wound-healing assay, tetracycline was
added at the beginning of the experiment (time 0)
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We recently reported results of CRISPR/Cas9-medi-
ated TP63 knock-out in the HCC1806 basal-A breast
cancer cell line [29]. The major findings from this model
were related to alterations of differentiation markers,
where p63 is required to suppress expression of luminal
markers and maintain the basal epithelial phenotype, but
p63 loss is insufficient to induce full luminal-type differ-
entiation. We also found that p63 depletion changed
expression of adhesion molecules in a similar manner to
that observed here, with reciprocal changes in FAT2,
ITGA2, CLDN1, LAMA4 and CEACAM6 following p63
depletion [29] or p63 induction (this manuscript). How-
ever, either over-expression or gene knockout each
caused a loss of cellular adhesion in the respective cell
lines, indicating that the consequences of manipulating
p63 levels are dependent on the cells under investiga-
tion, which likely relates to their dependence on p63 and
their different genetic backgrounds.
The results of gene expression profiling were used to
investigate cell phenotype, where induction of ΔNp63α
caused visible loss of MDA-MB-468 cell adhesion and
eventual cell detachment. Loss of cell adhesion was
accompanied by decreased proliferation and cell cycle
arrest and cell detachment caused decreased cell viability
after 3 days of ΔNp63α induction. The same effect was
observed in vivo in SCID mice, where induction of
ΔNp63α correlated with decreased tumour size. This is
contrary to the often reported importance of ΔNp63 for
maintenance of cell proliferation [66–68] suggesting that
p63 has a complex role in regulation of tumour cell fate.
However, it is in agreement with previously reported abil-
ity of ΔNp63α to induce cell cycle arrest and upregulate
GADD45 and CDKN1A genes [69]. Similar data for the ef-
fects of ΔNp63α on proliferation and adhesion were seen
in another basal-A (epithelial) type cell line, BT-20. Inter-
estingly, these effects were not seen in basal-B (mesenchy-
mal) type TNBC BT-549 cells, suggesting that ΔNp63α
has cell context specific effects that relate to epithelial/
mesenchymal cell phenotypes. This notion will require
further investigation, but mirrors the expression pattern
of p63 in primary human breast cancers, where p63 is a
defining characteristic of basal-A TNBCs and basal-B
mesenchymal-type TNBCs do not express p63 [38, 39].
Conclusions
In summary, we have produced MDA-MB-468 basal-type
breast cancer cells with inducible p63 expression vectors.
Although most of our data are derived only from this cell
line, we show that ΔNp63α had much stronger effects on
gene expression than TAp63α, questioning whether this
isoform has a physiological role in basal-type breast
cancer. Further studies using other cell lines will be re-
quired to assess the generality of the findings and may
indeed reveal further cell-context-dependent effects of
p63 in cancer. In addition, correlations between p63 and
the adhesion-related processes will be required in clinical
samples to understand the potential role of p63 on patient
outcome in basal-type breast cancer. In this respect,
although p63 is usually mentioned mostly in connection
with basal phenotype and stem cells in normal breast
tissue and breast cancer, we showed that a major effect of
p63 in MDA-MB-468 cells is regulation of cell adhesion, a
process important in metastasis and invasion of tumour
cells. We also found that ΔNp63α can inhibit cell prolifer-
ation in vitro and suppress tumour growth in vivo sug-
gesting context-dependent effects of p63 in cancer.
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